Evidence map›Paper›PMID 42343420›Full record

ArticleJournal of neuroinflammation2026

Immune checkpoint LAG-3 governs stage-dependent and disease-associated microglial modules in ALS model mice.

Yuta Morisaki, Nanaka Nomura, Motoki Ohshima, Miruto Matsuda, Okiru Komine, Takashi Okuda, Koji Yamanaka, Hidemi Misawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuta MorisakiDivision of Pharmacology, Faculty of Pharmacy, Keio University, Tokyo, Japan. morisaki-yt@keio.jp.
Nanaka NomuraDivision of Pharmacology, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Motoki OhshimaDivision of Pharmacology, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Miruto MatsudaDivision of Pharmacology, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Okiru KomineDepartment of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Takashi OkudaDivision of Pharmacology, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Koji YamanakaDepartment of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Hidemi MisawaDivision of Pharmacology, Faculty of Pharmacy, Keio University, Tokyo, Japan. hmisawa@keio.jp.

Funding

Japan Society for the Promotion of Science JP22K06634Japan Society for the Promotion of Science JP26K10309
6 · The paper itself

Abstract

Immune checkpoint molecules, inhibitory receptors originally characterized in T cell biology, have recently emerged as regulators of microglial function in neurodegeneration, yet their roles in amyotrophic lateral sclerosis (ALS) remain unexplored. Here, we investigated LAG-3, an inhibitory immune checkpoint receptor, in microglial regulation during ALS pathogenesis using SOD1

Indexed as

Amyotrophic Lateral SclerosisAntigens, CDMicrogliaAnimalsDisease Models, AnimalLymphocyte Activation Gene 3 ProteinMiceMice, Inbred C57BLMice, TransgenicSpinal CordAntigens, CDLag3 protein, mouseLymphocyte Activation Gene 3 ProteinAmyotrophic lateral sclerosisDisease-associated microgliaImmune checkpointLAG-3MicrogliaNeuroinflammation

Identifiers

PMID42343420
PMCPMC13428418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.